The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Drug testing in Europe: monitoring results of the Trans European Drug Information (TEDI) project
Abstract
Drug testing is a harm reduction strategy that has been adopted by certain countries in Europe. Drug users are able to hand in their drugs voluntarily for chemical analysis of composition and dose. Drug users will be alerted about dangerous test results by the drug testing systems directly and through warning campaigns. An international collaborative effort was launched to combine data of drug testing systems, called the Trans European Drug Information (TEDI) project. Drug testing systems of Spain, Switzerland, Belgium, Austria, Portugal, and the Netherlands participated in this project. This study presents results of some of the main illicit drugs encountered: cocaine, ecstasy and amphetamine and also comments on new psychoactive substances (NPS) detected between 2008 and 2013. A total of 45 859 different drug samples were analyzed by TEDI. The drug markets of the distinct European areas showed similarities, but also some interesting differences. For instance, purity of cocaine and amphetamine powders was generally low in Austria, whilst high in Spain and the Netherlands. And the market for ecstasy showed a contrast: whereas in the Netherlands and Switzerland there was predominantly a market for ecstasy tablets, in Portugal and Spain MDMA (3,4‐methylenedioxymethamphetamine) crystals were much more prevalent. Also, some NPS appearing in ecstasy seemed more specific for one country than another. In general, prevalence of NPS clearly increased between 2008 and 2013. Drug testing can be used to generate a global picture of drug markets and provides information about the pharmacological contents of drugs for the population at risk. Copyright © 2016 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Orsolini, L., Francesconi, G., Papanti, D., Giorgetti, A., & Schifano, F. (2015) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2466 · Cited by 70
Cited by
Fentanyl in the US heroin supply: A rapidly changing risk environment
Ciccarone, D. (2017) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2017.06.010 · Cited by 450
New psychoactive substances: challenges for drug surveillance, control, and public health responses
Peacock, A., Bruno, R., Gisev, N., Degenhardt, L., Hall, W., Sedefov, R., White, J., Thomas, K. V., Farrell, M., & Griffiths, P. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32231-7 · Cited by 360
Harper, L., Powell, J., & Pijl, E. M. (2017) · Harm Reduction Journal · doi:10.1186/s12954-017-0179-5 · Cited by 337
Fairbairn, N., Coffin, P. O., & Walley, A. Y. (2017) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2017.06.005 · Cited by 274
Drug checking services for people who use drugs: a systematic review
Maghsoudi, N., Tanguay, J., Scarfone, K., Rammohan, I., Ziegler, C., Werb, D., & Scheim, A. I. (2022) · Addiction · doi:10.1111/add.15734 · Cited by 261
Green, T. C., Park, J. N., Gilbert, M., McKenzie, M., Struth, E., Lucas, R., Clarke, W., & Sherman, S. G. (2020) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2020.102661 · Cited by 211
Karamouzian, M., Dohoo, C., Forsting, S., McNeil, R., Kerr, T., & Lysyshyn, M. (2018) · Harm Reduction Journal · doi:10.1186/s12954-018-0252-8 · Cited by 209
Palamar, J. J., Ciccarone, D., Rutherford, C., Keyes, K. M., Carr, T. H., & Cottler, L. B. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109398 · Cited by 147
Sherman, S. G., Morales, K. B., Park, J. N., McKenzie, M., Marshall, B. D. L., & Green, T. C. (2019) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2019.03.003 · Cited by 141
Metadata
- Authors
- Brunt, T. M., Nagy, C., Bücheli, A., Martins, D., Ugarte, M., Beduwe, C., & Ventura Vilamala, M.
- Venue
- Drug Testing and Analysis
- Publisher
- Wiley
- Published
- 2016-02-17
- Volume
- 9
- Issue
- 2
- Pages
- 188-198
- ISSN
- 1942-7603 (ISSN-L)
- 1942-7611
- OpenAlex
- W2276234421
- Cited by
- 178
- References
- 1
- FWCI
- 38.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.